JPMorgan lowered the firm’s price target on Sarepta (SRPT) to $20 from $28 and keeps an Overweight rating on the shares. So long as Elevidys stays on the market, there is upside to Sarepta shares, the analyst tells investors in a research note. The firm says Elevidys not staying on the market in ambulatory patients would be “thesis changing.” It cites a more conservative model approach for the target drop.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta downgraded to Underperform from Hold at Needham
- Buy Rating for Sarepta Therapeutics Amid Elevidys’ Continued Use in Ambulatory Patients
- Sarepta price target lowered to 0c from $10 at H.C. Wainwright
- Sarepta downgraded to Neutral from Outperform at Mizuho
- JPMorgan, Starbucks, HPE, Sarepta, Elevance: Trending by Analysts